News and publications
Promethera Biosciences reshapes its leadership team
Mont-Saint-Guibert, Belgium, January 23, 2015 - Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of inborn errors of metabolism and acquired liver diseases, today announces the resignation of Eric Halioua from his post as CEO of Promethera and all other functions within the company. He has decided to leave in order to concentrate on other projects.
PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01